Skip to content

Low-Grade Glioma (Brain Tumor)

Low-grade glioma was an umbrella term rather than one molecular diagnosis. It commonly referred to slower-growing central-nervous-system tumors with lower-grade microscopic features, but tumors within that group differed in biology, treatment, and long-term course.

Classification

Modern classification combined microscopic appearance with molecular findings. The major adult-type diffuse gliomas included astrocytoma, IDH-mutant, which could be assigned CNS WHO grades 2 through 4, and oligodendroglioma, IDH-mutant and 1p/19q-codeleted, which could be assigned grades 2 or 3. An infiltrating tumor could extend between functional brain cells without forming one clean surgical border.

The phrase ‘’low-grade’’ did not mean benign, harmless, or uniform. A grade 2 diffuse glioma could remain stable for years, recur after treatment, or progress to a higher grade. Its course could not be predicted from the word ‘’low-grade’’ alone. Circumscribed tumors such as pilocytic astrocytoma followed different biological and treatment patterns and were not interchangeable with adult-type diffuse glioma.

Presentation

Symptoms depended on the tumor’s location, size, rate of growth, surrounding swelling, and effects on functional networks. Slow growth allowed symptoms to accumulate gradually and sometimes delayed recognition.

Seizures were a common presentation and could precede diagnosis by months or years. A person could experience focal aware or impaired-awareness seizures, focal motor events, bilateral tonic-clonic seizures, seizure clusters, or status epilepticus.

Other possible effects included:

  • persistent or changing headache;
  • nausea, vomiting, appetite loss, or unusual sleepiness;
  • visual-field or other sensory change;
  • word-finding, speech, memory, attention, or processing difficulty;
  • altered mood, behavior, or personality; and
  • weakness, clumsiness, imbalance, or other location-dependent motor effects.

None of those symptoms established a brain tumor by itself. New seizures, progressive focal neurological changes, or a worsening cluster of symptoms required clinical assessment and appropriate imaging.

Diagnosis

Magnetic resonance imaging could show a lesion’s size, location, enhancement, swelling, and relationship to nearby structures. Computed tomography was often used in emergency evaluation, especially after a first seizure, but MRI provided more detailed characterization.

Imaging could suggest a diffuse glioma but could not reliably establish its complete type or grade. Tissue obtained through biopsy or resection was assessed by neuropathology. Integrated diagnosis incorporated histology and molecular findings, including IDH status and 1p/19q codeletion. Those findings distinguished oligodendroglioma from astrocytoma and informed prognosis and treatment.

Neurological, neuropsychological, speech-language, and visual-field assessment documented a person’s baseline before treatment. Functional MRI, tractography, and intraoperative mapping could help define an individual tumor’s relationship to language, movement, memory, vision, and other functions.

Treatment

Treatment was planned by a multidisciplinary neuro-oncology team. The plan depended on the integrated diagnosis, symptoms, age, functional status, residual tumor, prior treatment, and the person’s goals and tolerance for risk.

Surgery and Functional Mapping

Maximal safe resection aimed to remove as much tumor as possible while preserving neurological function. A subtotal resection could be the safer result when tumor cells extended into tissue necessary for language, movement, memory, vision, or other abilities.

Awake craniotomy was one method of intraoperative brain mapping. The person was awake for the functional-testing portion while the team stimulated small areas near the tumor and asked them to speak, count, name pictures, move, or complete other tasks. The responses identified tissue that needed to be preserved. Awake mapping was useful for selected tumors near functional networks; it was not required for every glioma operation.

Radiation and Systemic Treatment

Postoperative treatment was not identical for every grade 2 glioma. Some people with favorable features could undergo MRI surveillance after surgery. Others received radiation with chemotherapy because of residual tumor, symptoms, age, molecular type, progression, or other risk factors.

For grade 2 oligodendroglioma that was IDH-mutant and 1p/19q-codeleted, radiation with PCV chemotherapy was an established option. Temozolomide could be used as an alternative when PCV toxicity was a concern. For grade 2 IDH-mutant astrocytoma, radiation with adjuvant PCV or temozolomide was also used when postoperative treatment was indicated.

Vorasidenib became an option in 2024 for selected people aged twelve or older with a susceptible IDH1- or IDH2-mutant grade 2 astrocytoma or oligodendroglioma after surgery, particularly when radiation and chemotherapy could be deferred. It did not replace molecular diagnosis or make one treatment sequence universal.

Surveillance and Supportive Care

Serial MRI monitored residual tumor, treatment response, recurrence, and progression. Scan intervals changed with the tumor’s behavior and the stage of follow-up rather than following one permanent schedule.

Care could also include antiseizure medication, corticosteroids when clinically indicated for swelling, antiemetics, rehabilitation, speech-language therapy, occupational or physical therapy, vision rehabilitation, cognitive support, counseling, and palliative care. Palliative care could be used alongside tumor-directed treatment to address symptoms and quality of life.

Treatment Effects and Access

Surgery could temporarily or permanently affect speech, cognition, strength, sensation, vision, coordination, or seizure control. Brain radiation could cause cumulative fatigue, localized hair loss and scalp effects, headache, nausea, swelling, and cognitive change; some neurological effects emerged months or years later. Temozolomide could cause nausea, vomiting, fatigue, appetite loss, constipation, headache, hair loss, and bone-marrow suppression, and it required blood-count and liver monitoring.

The same outward difficulty could have different causes. Word-finding trouble, for example, could reflect the tumor, a seizure or postictal state, postoperative swelling, direct surgical effects, radiation, medication, fatigue, or several factors together. New or worsening changes required reassessment instead of automatic attribution to the original tumor.

Communication access included extra response time, direct address, supported decision-making, low-demand recovery periods, and alternate communication when speech was impaired. Visual-field loss could require scanning strategies and environmental changes. Seizure plans, transportation, medication organization, and reliable caregiving could determine whether treatment remained practically accessible.

Associated Character

Elliot Landry

Elliot was diagnosed in 2049, the year he turned forty-six, with a right-temporal oligodendroglioma, IDH1-mutant and 1p/19q-codeleted, CNS WHO grade 2. The tumor’s diffuse edges crossed individual functional boundaries identified during mapping; its location did not make right-sided language organization universal.

For months before diagnosis, Elliot experienced worsening headaches, nausea and vomiting, exhaustion, word-finding difficulty, memory lapses, focal events, and longer crashes after activity. Clinicians repeatedly attributed the pattern to his body size, stress, dehydration, and overwork. A severe heat-and-nausea episode at an Austin work event and a later roadside vomiting episode occurred during that escalation.

At a cookout at Charlie and Logan’s Baltimore home, Elliot had back-to-back seizures that progressed to convulsive status epilepticus. Emergency imaging revealed the tumor, and surgical pathology established the molecular diagnosis.

Elliot underwent an awake craniotomy with cortical mapping. Logan Weston remained nearby during the mapping portion, helped the team track Elliot against his known baseline, and anchored him through the testing; the neurosurgical and mapping team performed the operation. Elliot had a focal seizure during mapping. Approximately seventy-five percent of the tumor was removed before the surgical team reached functional boundaries that made further resection unsafe.

After postoperative recovery, Elliot completed several weeks of focal radiation followed by at least twelve cycles of temozolomide. The temozolomide course lasted about fourteen months, and the overall surgical, radiation, chemotherapy, and early-recovery period lasted approximately nineteen to twenty months.

Radiation brought cumulative fatigue, nausea, headaches, localized hair loss, and worsened word retrieval. During temozolomide treatment, Elliot experienced severe nausea and vomiting despite antiemetics, profound fatigue that could keep him asleep for most of the day during the worst cycles, and a loss of approximately sixty pounds. By cycle nine, the physical and emotional burden led to a breakdown in which he told Ayana Brooks that he could not keep performing strength for everyone around him. Ayana, Jazmine Landry, Jacob Keller, Logan, and their wider chosen family divided caregiving and practical support.

Follow-up imaging showed substantial reduction of the residual tumor. Elliot continued MRI surveillance and lived with left peripheral-vision loss, fatigue, scan anxiety, and mild expressive aphasia that became more noticeable when he was exhausted. A localized thin patch of hair remained after treatment.

Ayana became pregnant shortly after treatment ended, while Elliot was still recovering. Ariana Landry and Adrian Landry were born prematurely around 2051 and were not present during his diagnosis or treatment.

Historical Context

Early glioma classification relied primarily on microscopic resemblance to glial cells. Twentieth-century grading systems increasingly separated tumors by growth pattern and cellular features, while the 2016 and 2021 World Health Organization classifications made molecular findings central to adult diffuse-glioma diagnosis.

Awake cortical mapping developed from nineteenth- and twentieth-century work in epilepsy surgery and functional neuroanatomy and later became an important method for selected tumor resections. Temozolomide entered clinical use in the late 1990s. Molecularly targeted treatment expanded again when the United States Food and Drug Administration approved vorasidenib for selected IDH-mutant grade 2 astrocytoma and oligodendroglioma in 2024.

Sources

Medical Conditions Neurological Conditions Cancer Elliot Landry